Insmed Incorporated

NASDAQ:INSM

Biotechnology

Healthcare
$119.80 -2.77%

-$2.73 today

Market cap
$26.28B
Beta
0.77
P/E (TTM)
-17.4
EPS (TTM)
-$5.49
52W Low $90.39High $212.75

Volume 1.94M

Average 3.31M

INSM Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Insmed IncorporatedNASDAQ: INSM

Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026

Accounts receivables grows, but more slowly than its trailing trend

Q2 FY2026 accounts receivables of $37.16M (cash outflow) rose 505.0% year over year, behind the +1189.3% change in trailing-twelve-month accounts receivables. Sequentially, it fell 2.7% from the prior quarter. Over 3 fiscal years it compounded at +139.6% a year.

Context

  • Accounts receivables amounted to 14.6% of revenue in FY2025, up 11.0 pp from a year earlier.
  • Accounts receivables grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +505.0% toward the trailing-twelve-month pace of +1189.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$37.16M-2.7% QoQ
Last fiscal yearDec 2025
-$88.31M+582.9% YoY
LTMJun 2026
-$162.88M+1189.3% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+505.0%——
1 year+582.9%——
3-year CAGR+139.6%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(88.31M) USD
Year-over-year change
-582.9%

Accounts Receivables vs competitors

How INSM compares with its peers on the latest reported figures

  • INSM's LTM Jun 2026 accounts receivables of $162.88M is the 2nd largest of the 4 companies compared; the peer median is $69M.
  • Its year-over-year change of +1189.3% is the 2nd highest of 4, against a peer median of +258.2%.
  • Accounts receivables amounts to 14.3% of revenue for INSM, versus a peer median of 28.8%.
INSM Competitors Peer median
Accounts Receivables for INSM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TBPHTheravance Biopharma, Inc.LTM Mar 2026$176.65M +258.2%+115.2%160.9%
INSMInsmed IncorporatedLTM Jun 2026$162.88M +1189.3%+139.6%14.3%
LQDALiquidia CorporationLTM Jun 2026$129.93M +1833.7%+193.7%28.8%
UTHRUnited Therapeutics CorporationLTM Jun 2026$69M +177.9%+48.4%2.2%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding INSM) $69M+258.2%+115.2%28.8%

Competitors are the stored peer set for INSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(434.65M)(481.53M)(749.57M)(913.77M)(1.28B)
Depreciation & Amortization14.18M10.33M10.58M11.01M16.45M
Deferred Income Tax17.69M0000
Stock-Based Compensation46.02M57.69M74.78M96.84M152.71M
Change in Working Capital(58.58M)6.58M(39.22M)(3.18M)(80.3M)
Accounts Receivables(8.12M)(6.42M)(11.96M)(12.93M)(88.31M)
Inventory(17.46M)(1.71M)(13.61M)(17.04M)(31.52M)
Accounts Payables(7.58M)50.01M15.16M44.59M100.07M
Other Working Capital(25.43M)(35.3M)(28.8M)(17.79M)(60.55M)
Other Non-Cash Items52.04M6.5M167.18M125.22M252.9M
Operating Cash Flow(363.3M)(400.44M)(536.25M)(683.88M)(935.01M)
Capital Expenditures(7.29M)(9.88M)(13.29M)(21.92M)(32.56M)
Acquisitions (Net)(6.7M)24.71M3.42M00
Purchases of Investments(50.29M)(99.71M)(588.73M)(1.58B)(2.09B)
Sales of Investments57M75M375M1.02B2.09B
Other Investing Activities(57M)(24.71M)00(30M)
Investing Cash Flow(64.29M)(34.58M)(223.6M)(583.18M)(64.58M)
Debt Repayment336.34M349.4M(1.22M)147.39M(4.93M)
Common Stock Issued269.89M292.15M152.48M1.08B959M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities6.32M151.72M17.18M109.51M0
Financing Cash Flow612.55M793.27M168.44M1.34B954.07M
Effect of Forex Changes(933K)(996K)(250K)(1.31M)931K
Net Change in Cash184.03M357.25M(591.66M)72.66M(44.59M)
Free Cash Flow(370.59M)(410.32M)(549.54M)(705.81M)(967.58M)

Insmed Incorporated

NASDAQ:INSM

Intrinsic Alpha fair value

Locked

Current Price

$119.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.